1RT.F

Healthcare Biotechnology

Nuformix plc

€0.00

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

2.61M

Avg Volume

45,454

52W High

€0.02

52W Low

€0.00

Div. Yield

0.0%

Valuation

P/B Ratio

0.85

EV/EBITDA

-2.79

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(50.9%)

Return on Assets

(27.2%)

Liquidity & Leverage

Current Ratio

4.32

Quick Ratio

4.32

Total Cash

930,283

Total Debt

About

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc is based in London, the United Kingdom.